Skip to content
10-Q

Quarterly Report

Yew Bio-Pharm Group, Inc.

0001213900-20-022258

← back to feed
Filed
Aug 14, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2020 · Aug 13, 2020 51.7M sh
Short Term Debt Q2 2020 · Jun 30, 2020 $8.49M
Short Term Debt Q2 2020 · Dec 31, 2019 $8.54M
Cash And Equivalents Q2 2020 · Jun 30, 2020 $1.67M
Cash And Equivalents Q2 2020 · Dec 31, 2019 $742.29K
Cash And Equivalents Q2 2020 · Jun 30, 2019 $156.44K
Cash And Equivalents Q2 2020 · Dec 31, 2018 $521.67K
Stockholders Equity Q2 2020 · Jun 30, 2020 $41.4M
Stockholders Equity Q2 2020 · Dec 31, 2019 $41.39M
Stockholders Equity Q2 2020 · Jun 30, 2019 $42.68M
Stockholders Equity Q2 2020 · Dec 31, 2018 $41.09M
Current Liabilities Q2 2020 · Jun 30, 2020 $11.84M
Current Liabilities Q2 2020 · Dec 31, 2019 $10.48M
Total Liabilities Q2 2020 · Jun 30, 2020 $14.35M
Total Liabilities Q2 2020 · Dec 31, 2019 $12.81M
Current Assets Q2 2020 · Jun 30, 2020 $12.95M
Current Assets Q2 2020 · Dec 31, 2019 $11.67M
Total Assets Q2 2020 · Jun 30, 2020 $55.74M
Total Assets Q2 2020 · Dec 31, 2019 $54.21M
Shares Diluted Q2 2020 · Jun 30, 2019 51.7M sh
Shares Diluted Q2 2020 · Jun 30, 2019 51.82M sh
Capex Q2 2020 · Jun 30, 2019 $379
Operating Cash Flow Q2 2020 · Jun 30, 2019 $3.69M
Eps Diluted Q2 2020 · Jun 30, 2019 $0.03
Eps Diluted Q2 2020 · Jun 30, 2019 $0.03
Eps Basic Q2 2020 · Jun 30, 2019 $0.03
Eps Basic Q2 2020 · Jun 30, 2019 $0.03
Sga Expense Q2 2020 · Jun 30, 2019 $218.43K
Sga Expense Q2 2020 · Jun 30, 2019 $513.4K
Net Income Q2 2020 · Jun 30, 2019 $1.44M
Net Income Q2 2020 · Jun 30, 2019 $1.81M
Operating Income Q2 2020 · Jun 30, 2019 $1.14M
Operating Income Q2 2020 · Jun 30, 2019 $1.68M
Gross Profit Q2 2020 · Jun 30, 2019 $646.06K
Gross Profit Q2 2020 · Jun 30, 2019 $1.8M
Cost Of Revenue Q2 2020 · Jun 30, 2019 $11.92M
Cost Of Revenue Q2 2020 · Jun 30, 2019 $22.27M